乳腺癌
医学
癌症
三阴性乳腺癌
肿瘤科
CA15-3号
组织微阵列
内科学
转移
抗体-药物偶联物
癌症研究
靶向治疗
人口
临床意义
抗体
免疫学
单克隆抗体
环境卫生
作者
April A. N. Rose,Andrée‐Anne Grosset,Zhifeng Dong,Caterina Russo,Patricia A. MacDonald,Nicholas Bertos,Yves St‐Pierre,Ronit Simantov,Michael T. Hallett,Morag Park,Louis Arthur Gaboury,Peter M. Siegel
标识
DOI:10.1158/1078-0432.ccr-09-1611
摘要
PURPOSE: Although the murine orthologue of glycoprotein nonmetastatic B (GPNMB), Osteoactivin, promotes breast cancer metastasis in an in vivo mouse model, its importance in human breast cancer is unknown. We have examined the significance of GPNMB expression as a prognostic indicator of recurrence and assessed its potential as a novel therapeutic target in breast cancer. EXPERIMENTAL DESIGN: The clinical significance of GPNMB expression in breast cancer was addressed by analyzing GPNMB levels in several published gene expression data sets and two independent tissue microarrays derived from human breast tumors. GPNMB-expressing human breast cancer cell lines were further used to validate a toxin-conjugated anti-GPNMB antibody as a novel therapeutic agent. RESULTS: GPNMB expression correlates with shorter recurrence times and reduced overall survival of breast cancer patients. Epithelial-specific GPNMB staining is an independent prognostic indicator for breast cancer recurrence. GPNMB is highly expressed in basal and triple-negative breast cancers and is associated with increased risk of recurrence within this subtype. GPNMB expression confers a more migratory and invasive phenotype on breast cancer cells and sensitizes them to killing by CDX-011 (glembatumumab vedotin), a GPNMB-targeted antibody-drug conjugate. CONCLUSIONS: GPNMB expression is associated with the basal/triple-negative subtype and is a prognostic marker of poor outcome in patients with breast cancer. CDX-011 (glembatumumab vedotin) is a promising new targeted therapy for patients with metastatic triple-negative breast cancers, a patient population that currently lacks targeted-therapy options.
科研通智能强力驱动
Strongly Powered by AbleSci AI